ClinicalTrials.gg
RecruitingNCT07436702OPTIRAPEUpdated Mar 3, 2026

Optimal Time for Reperfusion in Acute Pulmonary Embolism

An observational study in Pulmonary Embolism (Diagnosis) and Pulmonary Embolism Acute, sponsored by Azienda ULSS 8 Berica. Recruiting at 7 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Azienda ULSS 8 Berica · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Pulmonary Embolism with a site in Italy — 6 open to participants now, 8 under way, 1 of them phase 3. Pulmonary Embolism · Italy.

Planned enrollment
17th of 28
500 · median 623
Started
2025
with 1 other
Observational
28 of 57
6 open now
Registered
56th of 57
by date

Among the 57 studies in Pulmonary Embolism with a site in Italy, this one is the 17th largest by planned enrollment of the 28 observational ones that give a count, is one of 2 that started in 2025, is one of 28 observational ones, and was the 56th registered.

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

6 of the 57 studies in Pulmonary Embolism with a site in Italy are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Pulmonary Embolism with a site in Italy, or all of them as a file.
02

Study summary

Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality worldwide. Current guidelines recommend early reperfusion for high-risk and intermediate-high-risk PE, yet systemic thrombolysis and percutaneous therapies are frequently underutilized, and no specific timing for reperfusion is defined, unlike in acute myocardial infarction or ischemic stroke. As most PE-related in-hospital deaths occur within the first hours and thrombus composition changes over time, defining an optimal reperfusion time window may improve survival and prevent hemodynamic deterioration. We therefore propose a national, multicenter, prospective observational study to evaluate the prognostic impact of reperfusion timing, using systemic thrombolysis or catheter-directed therapies, on in-hospital mortality and haemorrhagic or cardiovascular complications.

Read the detailed description

Pulmonary embolism (PE) is currently the third leading cause of cardiovascular mortality worldwide. According to international guidelines, patients who are hemodynamically unstable at presentation (classified as high-risk according to the current European Society of Cardiology classification) and those at intermediate-high risk-defined as patients who are hemodynamically stable at admission but present with right ventricular dysfunction and positive cardiac ischemia biomarkers and subsequently develop sudden hemodynamic deterioration, should undergo reperfusion as early as possible.

At present, reperfusion in these patients is mainly achieved through systemic thrombolysis or percutaneous treatments. However, these strategies are frequently underutilized because of patients' comorbidities and bleeding risk. Notably, current international guidelines do not define a specific time window within which reperfusion should be performed using either approach, in contrast to what is well established in guidelines for acute myocardial infarction and ischemic stroke.

Given that most in-hospital deaths related to PE occur within the first hours after symptom onset and hospital admission, and considering that the histological composition of thrombi undergoes time-dependent changes that may partially reduce the effectiveness of reperfusion therapies, identifying a temporal cutoff within which reperfusion confers maximal clinical benefit would be highly relevant. Such a cutoff could improve both patient survival and the prevention of hemodynamic deterioration when performing systemic or percutaneous reperfusion.

To address this knowledge gap, we propose a national, multicenter, prospective observational study that could also could serve as a platform for registry-based randomized clinical trials. The primary aim of the study is to identify optimal management strategies for patients with intermediate-high-risk or high-risk PE, with a particular focus on the most appropriate timing of systemic reperfusion or catheter-directed therapies (CDTs), when indicated, and to evaluate their prognostic impact. Specifically, the study will assess the relationship between reperfusion timing (systemic thrombolysis or CDTs) and in-hospital mortality. Additionally, the association between different reperfusion time windows and the occurrence of haemorrhagic or cardiovascular complications will be evaluated.

03

Conditions studied

  • Pulmonary Embolism (Diagnosis)
  • Pulmonary Embolism Acute

Keywords

  • Fibrinolysis
  • Anticoagulation
  • Catheter-directed treatments
  • Time of Reperfusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a confirmed diagnosis of high-risk or intermediate-high-risk pulmonary embolism according to the 2019 European Society of Cardiology guidelines.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Patients with a diagnosis of intermediate-high or high pulmonary embolism confirmed by computed tomography pulmonary angiography (CTPA), pulmonary angiography, or echocardiography (evidence of a floating thrombus in the right atrium or right ventricle, or proximal visualization of thrombus in the pulmonary artery).
  • Classified as high-risk or intermediate-high-risk according to the 2019 European Society of Cardiology guidelines.
  • Provision of for the processing of personal data.

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Patients in whom a diagnosis of acute high-risk or intermediate-high-risk pulmonary embolism has been excluded.
  • Inability to provide .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with intermediate-high or high-risk pulmonary embolism

    Patients with intermediate-high or high-risk pulmonary embolism stratified according to the ESC 2019 guidelines

06

What researchers measure

Primary outcomes

  1. Mortality

    Correlation between time to reperfusion (measured in hours from hospital admission to initiation of systemic thrombolysis or catheter-directed therapies \[CDTs\]) and in-hospital mortality rate (rate of patients) among patients with intermediate-high- and high-risk acute pulmonary embolism.

    Time frame: From enrollment to the end of treatment at 30 days

Secondary outcomes

  1. Complications

    Association between different reperfusion time windows and techniques and the occurrence of haemorrhagic or cardiovascular complications among patients with intermediate-high and high-risk with acute pulmonary embolism

    Time frame: From enrollment to the end of treatment at 30 days

07

Study locations

7 of 7 sites recruiting
  • UO Unità di Cure Intensive Cardiologiche e Cardiologia 1, Ospedale Niguarda, Milano
    Milan, Milano 20162, Italy
    Recruiting
    • Claudia Colombo, MD · Contactclaudia.colombo@ospealeniguarda.it · +390264442565
    • Claudia Colombo, MD · Principal investigator
    • Alice Sacco, MD · Sub investigator
    • Fabrizio Oliva, MD · Sub investigator
  • UOC di Cardiologia, Ospedali Riuniti Padova Sud, Monselice, Italia
    Monselice, Padova 35043, Italy
    Recruiting
  • IRCCS Policlinico San Matteo
    Pavia, Pavia 27100, Italy
    Recruiting
    • Leonardo De Luca, MD PhD · Contactl.deluca@smatteo.pv.it · +390382503158
    • Leonardo De Luca, MD PhD · Principal investigator
    • Stefano Ghio, MD PhD · Sub investigator
    • Guido Tavazzi, MD PhD · Sub investigator
  • UO di Sezione di Medicina Interna e Cardiovascolare, Ospedale Santa Maria della Misericordia, Perugia, Italia
    Perugia, Perugia 06129, Italy
    Recruiting
    • Cecilia Becattini, MD PhD · Contactcecilia.becattini@unipg.it · +390755786424
    • Maria Cristina Vedovati, MD PhD · Sub investigator
    • Cecilia Becattini, MD PhD · Principal investigator
  • UO di Cardiologia 1, Azienda Ospedaliero Universitaria Pisana, Pisa, Italia
    Pisa, Pisa 56126, Italy
    Recruiting
    • Rosalinda Madonna, MD PhD · Contactrosalinda.madonna@unipi.it · +39050996975
    • Rosalinda Madonna, MD PhD · Principal investigator
    • Raffaele De Caterina, MD PhD · Sub investigator
  • UO di Cardiologia, Azienda Ospedaliera Ordine Mauriziano di Torino
    Torino, Torino 10128, Italy
    Recruiting
  • UOC di Cardiologia, Ospedali dell'Ovest Vicentino, Arzignano, IItalia
    Arzignano, Vicenza 36071, Italy
    Recruiting
    • Claudio Bilato, MD PhD · Contactclaudio.bilato@aulss8.veneto.it · +390444931163
    • Claudio Bilato, MD PhD · Principal investigator
    • Chiara Dalla Valle, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Oct 2026, 11 months after the start.

Of 135 non-industry observational studies under Pulmonary Embolism, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 119. This study's planned 11 months is below that.

Counting every sponsor, half of 160 studies reached it within 47 months; a quarter within 21 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 27, 2026
StartActual
Nov 25, 2025
Primary completionEst.
Oct 30, 2026
CompletionEst.
Oct 30, 2026
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07436702
Lead sponsor
Azienda ULSS 8 Berica
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Nov 25, 2025
Primary completion
Oct 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Mar 3, 2026

Study contacts

Claudio Bilato, MD PhD
Contact
claudio.bilato@aulss8.veneto.it
+390444479106
Marco Zuin, MD MS
study director · Department of Translational Medicine, University of Ferrara, Italy
Claudio Bilato, MD PhD
principal investigator · Department of Cardiology, Azienda AULSS 8 Berica, Arzignano (Vicenza), Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion